Skip to main content

Cancer Harboring BRAF Alterations clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • FORE8394 in Participants With Cancer Harboring BRAF Alterations

    open to eligible people ages 10 years and up

    The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.

    at UCLA UCSF

Last updated: